摘要
目的:观察伊立替康联合奈达铂治疗中晚期宫颈癌的临床效果。方法:将96例中晚期宫颈癌患者随机分为对照组和研究组(n=48)。所有病人行宫颈癌根治术。在手术治疗的基础上,研究组进行伊立替康联合奈达铂治疗(伊立替康用量为160mg·(m2)-1,奈达铂60mg·(m2)-1一次性静滴给药)。比较两组的疗效和副作用。结果:对照组和研究组总有效率为74.99%和89.59%,两组有显著性差别。研究组毒副作用较轻,包括血液学毒性、胃肠道反应等。结论:伊立替康联合奈达铂治疗中晚期宫颈癌具有较好的疗效。
Objective： To observe the clinical effect of irinotecan and nedaplatin on middle and advanced stage cervical cancer. Methods： 96 patients with middle and advanced stage cervical cancer were divided into control group and study group （n=48）. All of the patients were treated with cervical cancer radical surgery. The study group was treated with irinoteean and nedaplatin （iri- notecan, 160 mg（m2）-1 , iv. ; nedaplatin, 60 mg（m2）-1 , iv. ）, additionally. The effect and side effect were observed. Results： The total effective rate of control group and study group were 74.99% and 89. 59% （P〈0. 05）. The side effects of the study group were slight. Conclusion： It is effective to treat middle and advanced stage cervical cancer with irinotecan and nedaplatin under cervical cancer radical surgery.
出处
《四川生理科学杂志》
2014年第4期175-176,共2页
Sichuan Journal of Physiological Sciences
关键词
宫颈癌
中晚期
伊立替康
奈达铂
Cervical cancer
Middle and advanced stage
Irinotecan
Nedaplatin
